2hyy: Difference between revisions
From Proteopedia
Jump to navigationJump to search
m Protected "2hyy" [edit=sysop:move=sysop] |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:2hyy.png|left|200px]] | [[Image:2hyy.png|left|200px]] | ||
{{STRUCTURE_2hyy| PDB=2hyy | SCENE= }} | {{STRUCTURE_2hyy| PDB=2hyy | SCENE= }} | ||
===Human Abl kinase domain in complex with imatinib (STI571, Glivec)=== | ===Human Abl kinase domain in complex with imatinib (STI571, Glivec)=== | ||
{{ABSTRACT_PUBMED_17164530}} | {{ABSTRACT_PUBMED_17164530}} | ||
==About this Structure== | ==About this Structure== | ||
[[2hyy]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2HYY OCA]. | [[2hyy]] is a 4 chain structure of [[Proto-oncogene tyrosine-protein kinase]] with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2HYY OCA]. | ||
==See Also== | ==See Also== | ||
*[[Imatinib]] | *[[Imatinib|Imatinib]] | ||
*[[Proto-oncogene tyrosine-protein kinase|Proto-oncogene tyrosine-protein kinase]] | |||
==Reference== | ==Reference== | ||
<ref group="xtra">PMID: | <ref group="xtra">PMID:017164530</ref><references group="xtra"/> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Non-specific protein-tyrosine kinase]] | [[Category: Non-specific protein-tyrosine kinase]] | ||
Revision as of 03:26, 26 July 2012
Human Abl kinase domain in complex with imatinib (STI571, Glivec)
Template:ABSTRACT PUBMED 17164530
About this Structure
2hyy is a 4 chain structure of Proto-oncogene tyrosine-protein kinase with sequence from Homo sapiens. Full crystallographic information is available from OCA.
See Also
Reference
- Cowan-Jacob SW, Fendrich G, Floersheimer A, Furet P, Liebetanz J, Rummel G, Rheinberger P, Centeleghe M, Fabbro D, Manley PW. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):80-93. Epub 2006, Dec 13. PMID:17164530 doi:https://dx.doi.org/10.1107/S0907444906047287
